Introduction
============

The pigment epithelium-derived factor (PEDF) belongs to the super family of serine protease inhibitors, and the major sources of circulating PEDF are liver and adipose tissues \[[@B1]-[@B3]\]. PEDF is characterized as a multifunctional protein possessing anti-angiogenic, anti-tumorigenic, anti-oxidant, anti-inflammatory, anti-thrombotic, and neuroprotective properties. Demonstrated as a highly effective anti-angiogenic factor, PEDF not only is capable of inhibiting vascular endothelial growth and migration, but can also suppress secretion of angiogenic factors \[[@B4],[@B5]\] as well as activate the FAS-FAS ligand death pathway to stimulate endothelial cell apoptosis \[[@B6]\]. Nakamura et al. reported anti-oxidative effects of PEDF, showing that PEDF-mediated suppression of NADPH oxidase inhibited generation of reactive oxygen species and the subsequent neointimal hyperplasia induced by balloon injury \[[@B7]\]. Takenaka et al. also showed a cardio-protective function by which PEDF inhibited occlusive thrombus formation in the carotis artery of a rat model \[[@B8]\]. Finally, various studies have demonstrated the strong anti-inflammatory activities of PEDF; for example, PEDF was characterized both as a regulator of cytokines' expression such as monocyte chemoattractant protein-1 and tumor necrosis factor-α as well as a mediator of macrophage and T cell function \[[@B9]-[@B11]\].

PEDF may rely on any of these protective properties to manifest a counteractive mechanism during the development of atherosclerosis and cardiovascular disease. Recent clinical findings have revealed that PEDF levels are closely associated with the presence of cardiovascular disease. Circulating PEDF levels were shown to be higher in subjects with metabolic syndrome (MetS) and to be correlated with the extent of MetS components \[[@B12]-[@B14]\]. The fact that MetS itself, and each of its components, are important risk factors of cardiovascular disease which has led researchers to hypothesize that increased PEDF levels might have occurred as a counter-regulatory response to the presence of vascular injury. A recent study showed that serum PEDF level was independently correlated with intima-media thickness and vascular inflammation, suggesting an association of PEDF with subclinical atherosclerosis in at least two aspects: morphological abnormalities of the vessel, and inflammation in the plaques \[[@B15]\].

The above clinical findings revealed that PEDF levels were closely associated with the presence of cardiovascular disease, however, no study to date has focused on the relationship between serum PEDF and coronary artery disease (CAD). Since such data may also help to identify PEDF as a promising therapeutic target for atherosclerosis and cardiovascular disease \[[@B16],[@B17]\], the present study was carried out with Chinese patients who underwent coronary angiography to investigate the association between serum PEDF and CAD.

Materials and methods
=====================

Study population
----------------

A total of 312 participants (206 men and 106 women; age range: 38 \~ 86 years, mean age: 66.2 ± 10.1 years) who were admitted to the Department of Cardiology of Shanghai Jiao Tong University Affiliated Sixth People's Hospital to undergo coronary angiography because they have once suffered or was just suffering from chest tightness and/or chest pain between July 2008 and January 2010 were enrolled in the study. Patients were excluded from enrollment according to: serious hepatic or renal dysfunction; acute myocardial infarction within the past three months; coronary by-pass surgery or percutaneous coronary intervention within the past six months; congestive heart failure (defined as New York Heart Association functional class III-IV); acute infection; or history of malignancy. All women were postmenopausal. All enrollees completed a standardized questionnaire to self-report past and present illnesses, medications, and smoking habits. Enrollees who identified themselves as regular smokers, or who reported smoking at least one cigarette per day for at least the past six months, were classified as current smokers \[[@B18]\]. The study was approved by the Ethics Committee of Shanghai Jiao Tong University affiliated Sixth People's Hospital and complied with the Declaration of Helsinki. All the subjects provided written informed consent prior to the study participation.

According to the criteria of the 2007 Chinese Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults \[[@B19]\], MetS was diagnosed if a patient had three or more of the following: 1) central obesity, defined as waist circumference (W) of \>90 cm for men and \>85 cm for women; 2) fasting triglyceride (TG) of ≥1.7 mmol/L, or receipt of specific treatment for previously diagnosed hypertriglyceridemia; 3) fasting high-density lipoprotein cholesterol (HDL-c) of \<1.04 mmol/L, or receipt of specific treatment for previously diagnosed low HDL-c; 4) systolic blood pressure (SBP) of ≥130 mmHg and/or diastolic BP (DBP) of ≥85 mmHg, or receipt of treatment for previously diagnosed hypertension; 5) fasting plasma glucose (FPG) of ≥6.1 mmol/L and/or 2 h postprandial glucose (2hPG) of ≥7.8 mmol/L, or receipt of hypoglycemic therapy for previously diagnosed type 2 diabetes.

Coronary angiography
--------------------

Each study participant underwent coronary angiography by the standard Judkins technique \[[@B20]\]. All major coronary arteries were imaged in at least two orthogonal views. The angiographic analysis was performed by two experienced cardiologists who were blinded to the patients' clinical information. Patients with ≥50% diameter lumen stenosis in a major coronary artery (left main coronary artery, left anterior descending artery or its first diagonal branch, left circumflex artery or its first obtuse marginal branch, and right coronary artery) were classified as CAD.

Anthropometric evaluation
-------------------------

Each study participant underwent complete physical examination to obtain measurements of height, weight, W, and BP. Body mass index (BMI) was calculated as: \[(weight in kg)/(height in m)^2^\]. W was measured at the midpoint between the inferior margin of 12th rib and the iliac crest on the mid-axillary line.

Laboratory measurements
-----------------------

Blood samples were collected after 10 h overnight fast and stored at −80°C until use. Study participants without a history of diabetes received the standard 75 g oral glucose tolerance test. All participants' samples were assayed for FPG and 2hPG by the standard glucose oxidase method. Fasting insulin was measured via radioimmunoassay (Linco Research, St. Charles, MO, USA) and insulin resistance was estimated using the homeostasis model assessment index (HOMA-IR) \[[@B21]\]. Glycated hemoglobin (HbA1c) level was measured by high-pressure liquid chromatography (Bio-Rad Inc., Hercules, CA, USA). Serum creatinine (SCr), uric acid (UA), and lipid profiles, including TG, total cholesterol (TC), HDL-c and low-density lipoprotein cholesterol (LDL-c), were assayed by standard enzymatic procedures on an automated bioanalyzer (7600--020; Hitachi, Tokyo, Japan). The estimated glomerular filtration rate (eGFR; expressed as mL/min/1.73 m^2^) was calculated according to the equation from the Modification of Diet in Renal Disease (MDRD) study: \[186 \* (SCr/88.4)^-1.154^ \* (age)^-0.203^ \* 0.742 (if female)\] \[[@B22]\]. Serum C-reactive protein (CRP) was measured by a particle-enhanced immunonephelometry assay (Dade Behring Inc., Newark, NJ, USA). The 24 h urine albumin (24hALB) concentration was determined by standard rate nephelometry method. Sandwich enzyme immunoassays were used to detect the levels of PEDF (BioVendor Laboratory Medicine, Modrice, Czech Republic) and adiponectin (Li Ka Shing, Faculty of Medicine, University of Hong Kong, China). The inter- and intra-assay coefficients of variation were \<6.6% and \<4.1% for PEDF, and \<8.6% and \<7.3% for adiponectin, respectively.

Statistical analysis
--------------------

All statistical analyses were carried out with the Statistical Package for Social Sciences software (version 16.0; SPSS, Chicago, IL, USA). The clinical and biochemical data of the subjects are presented as mean ± SD, except for skewed variables that are presented as median with interquartile range of 25-75%. Two-tailed tests and a 5% level of significance were applied for all statistical analyses. Intergroup comparisons of variables with normal distribution were carried out by the unpaired Student's *t-*test; variables with non-normal distribution were compared by the Wilcoxon rank-sum test. For dichotomous or categorical variables, intergroup comparisons were carried out by the Chi-squared (χ^2^) test. Spearman's correlation was used to assess the relation between serum PEDF and other clinical parameters. Multiple logistic regression analysis was performed to identify factors that were independently correlated with CAD; CAD was set as the dependent variable and age, BMI, PEDF, CRP, HOMA-IR, adiponectin, CAD family history, smoking status, hypoglycemic therapy, anti-hypertensive therapy, lipid-lowering therapy, components of MetS (including central obesity, hyperglycemia, hypertension, hypertriglyceridemia, and low HDL-c), as well as MetS itself were assessed as the independent variables. Multivariate stepwise regression analysis was used to further assess the independent correlated clinical parameters of serum PEDF; serum PEDF was set as the dependent variable and age, BMI, W, glucose levels, BP, lipid profiles, HOMA-IR, CRP, adiponectin, 24hALB, eGFR, UA, hypoglycemic, anti-hypertensive, and lipid-lowering therapy were assessed as the independent variables.

Results
=======

Clinical characteristics of study participants
----------------------------------------------

The overall average of serum PEDF was 10.9 (8.1, 13.8) μg/mL for the entire study population. The average serum PEDF level was not significantly different between the male and female patients (10.7 (8.0, 13.9) vs. 11.1 (8.4, 13.2) μg/mL; *P* \> 0.05).

Compared with non-CAD subjects, CAD patients showed significantly higher age, 2hPG, HbA1c, and SCr, but significantly lower level of HDL-c (all *P* \< 0.05; Table [1](#T1){ref-type="table"}). The frequency of low HDL-c was significantly higher in CAD patients (*P* \< 0.05), while the frequency of MetS and other components of MetS showed no difference between the CAD and non-CAD groups (all *P* \> 0.05). In addition, the proportion of patients with hypoglycemic therapy and lipid-lowering therapy was significantly higher in the CAD group than in the non-CAD group (both *P* \< 0.05).

###### 

Characteristics of patients according to the presence or absence of CAD

  **Parameters**                     **Non-CAD**            **CAD**              ***P***
  ---------------------------------- ---------------------- -------------------- ---------
  n (male/female)                    84 (43/41)             228 (163/65)         0.001
  Age, years                         64.0 ± 9.9             67.0 ± 10.0          0.018
  Body mass index, kg/m^2^           24.8 ± 3.9             24.5 ± 3.0           0.520
  Waist circumference, cm            89.6 ± 10.9            90.6 ±8.9            0.408
  Fasting plasma glucose, mmol/L     5.5 (5.0, 6.0)         5.5 (5.0, 6.4)       0.448
  2h postprandial glucose, mmol/L    8.2 (6.2, 9.8)         8.8 (6.7, 12.4)      0.031
  Glycated hemoglobin A1c, %         6.0 (5.6, 6.5)         6.2 (5.8, 6.9)       0.005
  Fasting insulin, mU/L              16.3(11.9, 22.2)       16.5 (12.0, 24.5)    0.431
  HOMA-IR                            4.0 (2.8, 6.0)         4.0(2.8, 5.9)        0.939
  Systolic blood pressure, mmHg      130.0 (120.0, 150.0)   130 (120.0, 150.0)   0.335
  Diastolic blood pressure, mmHg     80.0 (70.0, 85.8)      80.0 (70.0, 83.8)    0.569
  Total cholesterol, mmol/L          4.5 ± 1.1              4.3 ± 1.1            0.070
  Triglyceride, mmol/L               1.5 (1.0, 2.2)         1.5 (1.1, 2.2)       0.461
  HDL-c, mmol/L                      1.2 ± 0.3              1.1 ± 0.3            0.018
  LDL-c, mmol/L                      3.1 ± 0.9              2.9 ± 1.0            0.221
  C-reactive protein, mg/L           1.4 (0.6, 3.6)         1.4 (0.6, 4.0)       0.329
  Adiponectin, μg/mL                 8.4 (5.6, 11,9)        7.1 (4.7, 12.1)      0.113
  Serum creatinine, μmol/L           72.0 (61.0, 87.3)      79.0 (68.0, 91.0)    0.008
  Uric acid, μmol/L                  324.4 ± 85.5           352.3 ± 90.6         0.392
  eGFR, mL/min/1.73m^2^              90.7 ± 25.1            85.5 ± 23.2          0.092
  24h urine albumin, mg/d            7.5 (5.1, 14.1)        7.1 (4.9, 18.3)      0.775
  CAD family history, n (%)          35 (41.6)              106 (46.5)           0.243
  Smoking, n (%)                     31 (36.9)              107 (46.9)           0.073
  Metabolic syndrome, n (%)          51 (60.7)              146 (64.0)           0.340
  Central obesity, n (%)             46 (56.1)              132 (58.9)           0.376
  Hyperglycemia, n (%)               51 (60.7)              147 (64.5)           0.314
  Hypertension, n (%)                71 (84.5)              206 (90.4)           0.109
  Hypertriglyceridemia, n (%)        34 (40.5)              89 (39.0)            0.458
  Low HDL-c, n (%)                   33 (39.3)              117 (51.3)           0.039
  Hypoglycemic therapy, n (%)        12 (14.3)              60 (26.3)            0.016
  Anti-hypertensive therapy, n (%)   54 (64.3)              166 (72.8)           0.094
  Lipid-lowering therapy, n (%)      11 (13.1)              80 (35.1)            \<0.001

Data are mean ± SD or median (interquartile range). CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HDL-c, high-density lipoprotein cholesterol; HOMA-IR, homeostatic model assessment-insulin resistance; LDL-c, low-density lipoprotein cholesterol.

Association of serum PEDF levels with MetS
------------------------------------------

Serum PEDF levels were significantly higher in subjects with MetS than in those without MetS (11.1 (8.2, 14.2) vs. 10.1(7.6, 12.4) μg/mL; *P* \< 0.05; Figure [1](#F1){ref-type="fig"}a). Spearman's correlation analysis showed that serum PEDF was positively correlated with hypertriglyceridemia (R = 0.213, *P* \< 0.001), but no significant correlation was observed among other components of MetS.

![**Comparison of serum PEDF levels between study participants with and without MetS (a) and CAD (b).** The bars represent median, 25th and 75th percentile of PEDF level.](1475-2840-12-56-1){#F1}

Correlation of serum PEDF and CAD
---------------------------------

As shown in Figure [1](#F1){ref-type="fig"}b, CAD patients had significantly higher levels of serum PEDF than non-CAD subjects (11.0 (8.1, 14.2) vs. 10.3 (8.1, 12.8) μg/mL; *P* \< 0.05). Multivariate logistic regression analysis indicated that age, PEDF and lipid-lowering therapy were independently positively correlated with CAD (Table [2](#T2){ref-type="table"}).

###### 

Multivariate logistic regression analysis showing factors independently associated with CAD

  **Independent variable**   **B**   **S.E.**   ***P***   **OR**   **95% CI**
  -------------------------- ------- ---------- --------- -------- --------------
  Age                        0.028   0.014      0.037     1.029    1.002-1.057
  PEDF^a^                    1.661   0.773      0.022     5.267    1.157-23.978
  Lipid-lowering therapy     1.076   0.360      0.003     2.933    1.449-5.934

Variables of the original model included: age, BMI, PEDF, CRP, HOMA-IR, adiponectin, central obesity, hyperglycemia, hypertension, hypertriglyceridemia, low HDL-c, MetS, CAD family history, smoking, hypoglycemic therapy, anti-hypertensive therapy, and lipid-lowering therapy.

^a^ Logarithmically transformed before analysis.

Influencing factors of serum PEDF levels
----------------------------------------

Table [3](#T3){ref-type="table"} shows the correlation analysis results for serum PEDF with the various anthropometric variables and clinical parameters. Serum PEDF was found to be positively correlated with FPG, HbA1c, HOMA-IR, TG, CRP, SCr and UA, and negatively correlated with eGFR. Stepwise multivariate regression analysis indicated that TG, CRP, eGFR, and hypoglycemic therapy were independently correlated with serum PEDF (Table [4](#T4){ref-type="table"}).

###### 

Correlation between clinical characteristics and serum PEDF

  **Variable**                           **R**    ***P***
  -------------------------------------- -------- ---------
  Age                                    0.024    0.673
  Gender                                 0.015    0.794
  Body mass index                        0.062    0.277
  Waist circumference                    0.095    0.096
  Fasting plasma glucose                 0.138    0.015
  2h postprandial glucose                0.078    0.167
  Glycated hemoglobin A1c                0.114    0.047
  HOMA-IR                                0.139    0.019
  Systolic blood pressure                0.040    0.480
  Diastolic blood pressure               −0.048   0.397
  Total cholesterol                      0.093    0.104
  Triglyceride                           0.263    \<0.001
  High-density lipoprotein cholesterol   −0.052   0.362
  Low-density lipoprotein cholesterol    0.005    0.932
  C-reactive protein                     0.191    0.001
  Adiponectin                            −0.032   0.577
  Serum creatinine                       0.187    0.001
  Estimated glomerular filtration rate   −0.203   \<0.001
  Uric acid                              0.152    0.008
  24h urine albumin                      0.120    0.052

###### 

Stepwise multivariate regression analysis of serum PEDF levels

  **Independent variable**   **Β**    **S.E.**   **Standardized β**   ***P***
  -------------------------- -------- ---------- -------------------- ---------
  Triglyceride ^a^           0.167    0.046      0.239                \<0.001
  CRP ^a^                    0.044    0.019      0.148                0.022
  eGFR                       −0.001   0.000      −0.173               0.008
  Hypoglycemic therapy       0.085    0.028      0.191                0.003

Variables of the original model included: age, BMI, W, FPG, 2hPG, HbA1c, SBP, DBP, TC, TG, HDL-c, LDL-c, HOMA-IR, CRP, adiponectin, 24hALB, eGFR, UA, hypoglycemic therapy, anti-hypertensive therapy, and lipid-lowering therapy.

^a^ Logarithmically transformed before analysis.

Discussion
==========

MetS is well recognized as an aggregate of cardio-metabolic risk factors subsequent cardiovascular disease and type 2 diabetes mellitus \[[@B23],[@B24]\], and the association of PEDF with MetS and its components has been verified in previous studies \[[@B12]-[@B14]\]. In a 10-year prospective study, enhanced PEDF level was identified as an independent predictor for the development of MetS in men \[[@B13]\], which further affirmed the prediction effect of PEDF on MetS. However, these studies focused solely on subjects with CAD risk factors but no clinical evidence of cardiovascular disease, which may have limited their ability to extend this relation of serum PEDF with MetS to the subsequent onset of cardiovascular disease. To overcome this limitation, the present study enrolled CAD and non-CAD subjects (\~3:4 ratio) as well as MetS and non-MetS subjects (\~2:3 ratio) and still found that serum PEDF level was significantly increased in the MetS patient group. This finding agrees with previous functional studies that indicated enhanced levels of PEDF might exert a counteractive activity against simultaneous enhancement of CAD risk factors \[[@B13],[@B14]\].

In the current study of the broad panel of MetS pathogenic components, PEDF was found to be significantly positively correlated with hypertriglyceridemia, and TG was identified as an independent influencing factor of serum PEDF levels. Dyslipidemia is known to play an important role in the development of atherosclerosis and CAD. Specifically, long-term dyslipidemia has been shown to cause physical injury to the vascular intima, and the accompanying pro-inflammatory state of the tissue promotes atherosclerosis and CAD. In clinical studies, patients with elevated TG levels developed CAD more frequently than their counterparts with TG levels in the normal range and TG has been identified as an independent risk factor for coronary events \[[@B25],[@B26]\]. In the current study, TG was found to be strongly and independently correlated with serum PEDF in patients with CAD or at high risk of CAD. Moreover, these findings also agree with the previous studies in patients without CAD history \[[@B12],[@B13]\]. It is possible that the enhanced levels of serum PEDF in CAD or CAD-risk patients reflect a response to hypertriglyceridemia, whereby the body is attempting to correct the perturbance in the lipid metabolism system \[[@B27]\]. Intriguingly, we failed to find any significant association of serum PEDF with the other two principal components of MetS, central obesity and hypertension. These negative findings may be explained by the fact that a large portion of our subjects had been receiving therapeutic treatments for hyperglycemia, hypertension, or hyperlipidemia for long periods prior to study participation; to account for this potential confounding aspect, hypoglycemia therapy was entered the equation in the multiple regression analysis of PEDF levels. Body weight and W in subjects of this study might have changed in response to a long-term influence of medications; therefore, the relation of PEDF with obesity might be masked by other determinants.

Substantial evidence exists to support the hypothesis that PEDF plays a protective role against microangiopathy; moreover, PEDF has been proposed as a potential protective factor against diabetic microvascular complications \[[@B28]-[@B30]\]. Yet, few studies to date have investigated the association of PEDF with macroangiopathy, as was done in the current study which demonstrated for the first time that serum PEDF was independently positively correlated with CAD in a Chinese population. This finding contradicts a previous study by Shiga et al., which showed no significant correlation between PEDF and the presence of CAD in a Japanese population \[[@B31]\]; however, this apparent inconsistency may merely indicate the different inclusion subjects.

Atherosclerosis, which is considered the pathological basis of CAD, is a chronic inflammatory disorder \[[@B32]\]. Previous studies have shown that CRP was positively correlated with PEDF, and suggested that this relation may reflect the body's attempt to suppress a detrimental inflammatory reaction involving the endothelial cells \[[@B14],[@B33]\]. In our study, we found no difference in the CRP levels of CAD and non-CAD patients, possibly because the majority of those non-CAD patients actually possessed many of the CAD risk factors and \>60% of them were MetS patients. Regardless, the multivariate stepwise regression analysis performed for the study population identified CRP as an independent influencing factor of serum PEDF levels, and this finding agrees with the proposed association of PEDF with chronic inflammation. Furthermore, oxidative stress, which is elevated in patients with metabolic disorder or CAD, could be one of the triggers in the liver (an important source organ of circulating PEDF), as hydrogen peroxide has been shown to induce PEDF expression in human hepatocytes \[[@B34]\].

Given the fact that PEDF exerts anti-angiogenic, anti-oxidative, anti-thrombotic, and anti-inflammatory properties on vascular tissues, researchers have speculated that PEDF levels might be elevated to counteract generation of a pro-atherosclerotic environment induced by vascular injuries \[[@B16],[@B17]\]. Ueda et al. reported that PEDF injection suppressed cardiac fibrosis, inhibited tissue remodeling and improved cardiac function in a rat model of acute myocardial infarction and suggested that PEDF may be a novel therapeutic strategy for human acute myocardial infarction \[[@B35]\]. Since PEDF exerts a number of protective effects on vascular and myocardial tissues, elevated serum PEDF levels in CAD patients may also play a counter-regulatory and protective role against vascular damage caused by hypertriglyceridemia, hyperglycemia, and chronic inflammation.

Moreover, Rychli et al. found that PEDF was significantly associated with CAD (for trend, *P* = 0.037) and correlated with rehospitalization for heart failure (HF) worsening, with a more prominent risk increase association in CAD patients; these previous findings further support our current results. Rychli et al. also suggested that PEDF was associated with chronic deterioration of cardiomyopathy and played a role in the progression of HF by inducing apoptosis of human cardiac myocytes and fibroblasts \[[@B36]\]. We believe that the elevated PEDF observed in CAD patients occurs in response to vascular injuries, chronic inflammation, and oxidative stress, and that its function involves preventing CAD deterioration.

It has been reported that cardiovascular disease was closely regulated through the signaling pathways of the mammalian target of rapamycin (mTOR) which was associated with endothelial cell survival and growth, as well as cardiomyocyte proliferation \[[@B37]\]. Wang et al. confirmed the antiangiogenic property of PEDF and firstly reported that insulin could down-regulate PEDF expression, which at least partly depended on mTOR kinase as the inhibitory effect of insulin on PEDF expression would disappear when added the mTOR inhibitor rapamycin \[[@B38]\]. It is possible that PEDF would offer exciting prospects for the development of new therapies for cardiovascular disease.

Another physiological factor that was correlated with the elevated PEDF levels in our study population was eGFR (independently negatively correlated). This finding is not surprising since renal filtration is known to affect serum PEDF levels, and is in line with findings from previous studies \[[@B15],[@B31]\].

Limitations
===========

When interpreting the results from our present study, it is important to consider some of the features of the study design that may limit the generalizability of our findings. Firstly, the cross-sectional design of the current study precluded our ability to determine the cause-effect relationship for PEDF and CAD. Secondly, the study population was relatively small, and larger prospective studies are necessary to confirm the role of PEDF in the development of CAD. Moreover, the study population was composed of individuals who were suspected of CAD (admitted to hospital to undergo coronary angiography) and most had several of the known risk factors of CAD, which may have biased the results.

Conclusions
===========

Nonetheless, the population of Chinese patients assessed in this study demonstrated a significantly independent correlation of serum PEDF with the presence of CAD. Biologically, PEDF is capable of exerting a number of protective effects under conditions of metabolic disorder, and the mechanism fits with the observation of elevated serum PEDF in patients with MetS and CAD. In particular, elevated serum PEDF levels may represent a counter-regulatory mechanism that acts as a protective response against vascular damage and subsequent CAD. Molecular targeting of PEDF might be a promising therapeutic strategy for treatment of cardiometabolic disorders and represent a useful predictive index for treatment effectiveness. Further laboratory and clinical studies are warranted to confirm the protective effect of PEDF on cardiovascular disease and to assess its potential as a therapeutic target.
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